Activated Charcoal Antimony Trisulfide Calcium Sul

證據等級: L5

預測適應症: 0 個

ACTIVATED CHARCOAL / ANTIMONY TRISULFIDE / CALCIUM SULFIDE / DAPHNE MEZEREUM BARK / POTASSIUM ARSENITE ANHYDROUS / SEMECARPUS ANACARDIUM JUICE / TOXICODENDRON PUBESCENS LEAF: Repurposing Evaluation Not Feasible

One-Sentence Summary

This is a seven-component herbal-mineral combination containing substances from Ayurvedic and homeopathic traditions, currently not approved or marketed in Taiwan (or the United States). The TxGNN pipeline returned no predicted indications for this combination, and no clinical trials or literature were retrieved. Evaluation cannot proceed due to missing foundational data including regulatory approvals, mechanism of action, and model predictions.

Quick Overview

Item	Content
Original Indication	None identified
Predicted New Indication	None (no TxGNN output returned)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only (no actual studies via this pipeline)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction is Available

This candidate consists of seven heterogeneous active ingredients spanning multiple pharmacological categories:

Activated Charcoal — a broad-spectrum adsorbent with no specific pharmacological target
Antimony Trisulfide — a heavy-metal sulfide compound with undefined systemic activity
Calcium Sulfide — a mineral historically used in homeopathic skin preparations
Daphne Mezereum Bark — a botanical used in European folk medicine; contains toxic daphnin and mezerein
Potassium Arsenite Anhydrous — an arsenic salt; historically associated with Fowler’s Solution, used for various chronic conditions in the 19th century
Semecarpus Anacardium Juice — used in Ayurvedic medicine; contains bhilawanols with reported cytotoxic activity in preclinical studies
Toxicodendron Pubescens Leaf (Eastern Poison Oak) — used in homeopathic preparations at highly diluted doses

The TxGNN knowledge graph model requires a resolvable DrugBank ID to embed a compound into its drug-disease graph. Because this combination has no DrugBank registration, the model could not generate a prediction score or candidate indications. No original regulatory indication exists to anchor a repurposing hypothesis.

Currently, detailed mechanism of action data is not available. Based on available information, this appears to be a traditional compound preparation whose individual components span adsorbent, heavy-metal, botanical-alkaloid, and contact-allergen categories. Without a unified MOA or approved indication, a mechanistic bridge to any new indication cannot be established at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered for this combination.

Literature Evidence

Currently no related literature available through this pipeline for this combination.

Safety Considerations

Several components carry significant intrinsic hazard that warrants attention regardless of indication:

Potassium Arsenite Anhydrous: Arsenic compounds are classified as Group 1 human carcinogens (IARC). Systemic exposure carries risks of peripheral neuropathy, skin malignancies, and haematological toxicity.
Daphne Mezereum Bark: Contains daphnin and mezerein; ingestion may cause severe gastrointestinal toxicity and blistering.
Antimony Trisulfide: Antimony compounds can cause cardiac arrhythmia and hepatotoxicity at systemic doses.
Toxicodendron Pubescens Leaf: Contains urushiol; sensitization risk and severe allergic contact dermatitis.
Semecarpus Anacardium Juice: Contains skin- and mucosa-irritating bhilawanols; reported genotoxic activity in some in vitro models.

Formal drug-drug interaction data were not found (query status: not found). Package insert warnings and contraindications are unavailable because this combination holds no regulatory approval in any identified jurisdiction.

Conclusion and Next Steps

Decision: Hold

Rationale: This combination lacks the minimum data required for a repurposing evaluation — no approved indication, no DrugBank ID for model embedding, no TxGNN prediction output, and no safety profile from a regulatory source. Several components (arsenic salts, antimony compounds, Daphne mezereum) carry serious toxicity signals that would require extensive safety characterisation before any forward-looking evaluation is appropriate.

To proceed, the following is needed:

Resolve individual components as separate DrugBank entries and run component-level TxGNN predictions independently
Identify the originating formulation or commercial product (e.g., Ayurvedic patent medicine, homeopathic black salve) to anchor the historical indication
Conduct a systematic literature review for each active component individually (especially Semecarpus anacardium and Potassium arsenite, which have published preclinical oncology data)
Obtain a full toxicological profile for arsenic- and antimony-containing fractions before any repurposing hypothesis is advanced
Determine jurisdictional regulatory status (CDSCO, EMA, FDA homeopathic OTC framework) to assess whether any component has a recognised therapeutic category
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.